Malignant pleural mesothelioma (MPM) is an aggressive, highly lethal neoplastic disorder of the pleural lining of the lung associated with exposure to asbestos. In the United States, about 2,000–3,000 new cases of MPM are diagnosed annually (Carbon, Kratzke, & Testa, 2002). The prognosis is dismal, with a five-year overall survival rate of about 8% in the United States (Verschraegen, 2003).

Unfortunately, MPM generally presents at an advanced stage, and the prognosis is quite poor. Median survival is brief, about 6–18 months (Carbon et al., 2002). Available treatment options include surgery, radiotherapy, cytotoxic chemotherapy, and biotherapy. However, survival outcomes remain poor, and treatment is largely palliative and limited to supportive care. Because patients with MPM typically present at advanced age and have locally advanced disease and comorbid conditions, few are candidates for surgery. Although surgery can improve recurrence-free survival and provide palliative relief of pain and discomfort for patients with early-stage disease, less than 15% of these patients survive longer than five years (Vogelzang et al., 2003). Similarly, radiotherapy has been proven to be of limited value. Although radiotherapy is useful for the palliative treatment of painful metastases, curative radiotherapy is limited by the extent of tumor volume and potential toxicity to normal tissues (Scagliotti et al., 2003).

Many cytotoxic agents, such as cisplatin, doxorubicin, and gemcitabine, have been studied as single agents and in combinations in phase II trials. Results to date with conventional agents have been disappointing. Response rates in single-agent studies typically range from 0%–15%. Median overall survival in most single-agent studies has ranged from seven to nine months. However, several studies have reported median overall survival rates from 5–11 months (Scagliotti et al., 2003).

Unsatisfactory results with conventional agents prompted increased research using newer agents with novel mechanisms of action. Perhaps the most significant new development in the treatment of MPM is the recent approval by the U.S. Food and Drug Administration (FDA) of pemetrexed (Alimta® [Eli Lilly and Company, Indianapolis, IN]), a novel multitargeted antifolate, in combination with cisplatin for front-line treatment of MPM.

Pemetrexed represents a significant advance in the treatment of MPM. Subsequent to demonstrating modest single-agent activity (response rate 14.1%; median overall survival 10.7 months) in a phase II trial of 64 patients with MPM (Scagliotti et al., 2003), pemetrexed, in combination with cisplatin, demonstrated significantly improved survival and a significant increase in progression-free survival in a phase III study that pemetrexed and cisplatin chemotherapy significantly improved survival and had greater antitumor activity than cisplatin alone. The U.S. Food and Drug Administration recently approved pemetrexed with cisplatin for treating MPM. Nurses should become familiar with the proper preparation and administration of pemetrexed, including the necessity of supplementation with folic acid and vitamin B12. As with all drugs, careful attention must be paid to patient selection, laboratory monitoring, contraindications, and appropriate interventions in the event of adverse reactions or overdose.

Key Words: mesothelioma, antineoplastic combined chemotherapy protocols

Kristi K. Orbaugh, RN, MSN, RNP, AOCN®

No known cure exists for malignant pleural mesothelioma (MPM). The prognosis for patients with this relatively rare, asbestos-related malignancy of the pleural lining of the lung is quite poor. MPM treatment includes surgery, radiotherapy, and chemotherapy. Few patients, however, are candidates for surgery or radiotherapy, so chemotherapy is the only option for most patients. A phase III study found that pemetrexed and cisplatin chemotherapy significantly improved survival and had greater antitumor activity than cisplatin alone. The U.S. Food and Drug Administration recently approved pemetrexed with cisplatin for front-line treatment of MPM.

Submitted October 2003. Accepted for publication November 18, 2003. The author received an honorarium and writing assistance from Ross Communications Associates, Inc., Melville, NY, which, in turn, received financial compensation from the manufacturer of Alimta® [Eli Lilly and Company in Indianapolis, IN]. (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.)

Digital Object Identifier: 10.1188/04.CJON.242-247